Data hunters will be Big Pharma’s next prey

Exscientia

20/12/2021 10:52

(The author is a Reuters Breakingviews columnist.  The opinions
expressed are her own.)
    By Aimee Donnellan
    LONDON, Dec 20 (Reuters Breakingviews) - Drugmakers such as
AstraZeneca spend $160 bln annually trying to unearth new
treatments for diseases like cancer. The winners will be those
who can source and analyse data quickly. That makes artificial
intelligence experts
like Relay Therapeutics and Exscientia targets.    
    Full view will be published shortly.
    Follow @aimeedonnellan https://twitter.com/aimeedonnellan on
Twitter
    
    CONTEXT NEWS
    - British healthcare technology firm BenevolentAI said on
Dec. 6 it will merge with Odyssey Acquisition, an
Amsterdam-listed special-purpose acquisition company founded by
investment bankers Yoel and Michael Zaoui. BenevolentAI uses
artificial intelligence to accelerate drug discovery. 
    - Drugmakers globally spend $160 billion on new research and
development each year, according to the Association of the
British Pharmaceutical Industry.

 (Editing by Neil Unmack and Oliver Taslic)
 ((For previous columns by the author, Reuters customers can
click on  DONNELLAN/ 
SIGN UP FOR BREAKINGVIEWS EMAIL ALERTS https://bit.ly/BVsubscribe
 | Aimee.Donnellan@thomsonreuters.com; Reuters Messaging:
Aimee.Donnellan.thomsonreuters.com@reuters.net))